Literature DB >> 26894268

Tumor Suppressor in Lung Cancer-1 Is a Prognostic Predictor for the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.

Yegang Chen1, Yongjiao Yang, Li Liu, Shangren Wang, Hong Song, Xiaoqiang Liu.   

Abstract

OBJECTIVE: To investigate the relationship between the expression of tumor suppressor in lung cancer-1 (TSLC1) and clinicopathological characteristics of patients with non-muscle-invasive bladder cancer (NMIBC) and evaluate the prognostic significance of TSLC1.
METHODS: TSLC1 expression in 241 specimens of NMIBC was examined by immunohistochemistry. The correlation between TSLC1 expression and clinicopathological characteristics was evaluated using the chi-square test. The prognostic significance of TSLC1 was analyzed by univariate, multivariate analysis and Kaplan-Meier survival curves.
RESULTS: The total negative rate of TSLC1 expression was 47.3% in NMIBC. Decreased expression of TSLC1 was correlated with a higher clinical stage, higher pathological grade, the number of tumors, lager tumor size, tumor recurrence and progression. TSLC1 expression was an independent risk factor for predicting tumor recurrence (p = 0.005) and progression (p < 0.001).
CONCLUSION: Decreased expression of TSLC1 is correlated with the malignancy of NMIBC tissues and low TSLC1 expression may serve as a predictor for bladder cancer recurrence and progression.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26894268     DOI: 10.1159/000438492

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Role of 5-Aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells.

Authors:  Hui-Hui Zhang; Bo Huang; You-Han Cao; Qing Li; Han-Feng Xu
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

2.  Folic acid inhibits nasopharyngeal cancer cell proliferation and invasion via activation of FRα/ERK1/2/TSLC1 pathway.

Authors:  Zhibiao Liu; Xin Jin; Wen Pi; Shouhou Liu
Journal:  Biosci Rep       Date:  2017-12-05       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.